Corrigendum to "The second nationwide surveillance of antibacterial susceptibility patterns of pathogens isolated from skin and soft-tissue infections in dermatology departments in Japan" [J. Infect. Chemother. 29 (2023) 143-149].

The authors would like to correct the funding. Funding This study was supported by grants from the following pharmaceutical companies (in alphabetical order): Astellas Pharma Inc., Choseido Pharmaceutical Co., Ltd., Daiichi-Sankyo Co., Ltd., Daiichi-Sankyo Espha Co., Ltd., Fujifilm Toyama Chemical Co., Ltd., GlaxoSmithKline. K.K., Kobayashi Kako Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd., Nichi-Iko Pharmaceutical Co., Ltd., Nipro Corporation., Ohara Pharmaceutical Co., Ltd., Pfizer Japan Inc., Sawai Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takata Pharmaceutical Co., Ltd., Teva Takeda Pharma Ltd., Towa Pharmaceutical Co., Ltd., and Yoshindo Inc. The second nationwide surveillance of antibacterial susceptibility patterns of pathogens isolated from skin and soft-tissue infections in dermatology departments in JapanJournal of Infection and ChemotherapyVol. 29Issue 2PreviewThe present study compared trends in antimicrobial resistance patterns in pathogens isolated from skin and soft-tissue infections (SSTIs) in Japan with those of a nationwide survey conducted in 2013. Three organisms that caused most of the SSTIs were collected from 12 dermatology departments in medical centers and 12 dermatology clinics across Japan between April 2019 and August 2020. A total of 390 strains, including 267 Staphylococcus aureus, 109 coagulase-negative staphylococci (CNS), and 14 Streptococcus pyogenes strains were submitted to a central laboratory for antimicrobial susceptibility testing. Full-Text PDF